SHAREHOLDER NOTICE: Lundin Law PC Announces Investigation of Amicus Therapeutics, Inc. and Strongly Encourages Shareholders to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC announces it is investigating claims against Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (Nasdaq: FOLD) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Amicus were false and misleading concerning the Company’s financial performance.

To join this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at [email protected].

On October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year. When the truth was revealed, shares dropped harming investors.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151105007041/en/

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]

Source: Lundin Law PC

You May Also Be Interested In

• Seyond's High-Performance LiDAR Technology Powers the Future of Autonomous Racing
• RECONAFRICA ANNOUNCES AN OPERATIONS UPDATE, JOINT VENTURE UPDATE AND CONFERENCE EVENT
• Glo Fiber Announces Broadband Expansion in Ohio